PDCD1 and acute myeloid leukemia: It should be noted that although previous reports have demonstrated increased efficacy of PD-1/PD-L1 blocker in MDS/AML cases after allo-HSCT, unfavorable high risk of graft-versus-host disease (GVHD) was also reported [145–147].